Payment overview · 2025
General Payments
$873.03
62 reported records · 13 companies
Healthcare provider profile · identity verified
William D Robinson, DO
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1891176111
Verified facts
What the public records show
CMS Open Payments records show William D Robinson, DO received $873.03 in general payments during 2025 across 62 reported records.
Novo Nordisk Inc accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $177.03 | 20.3% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.11 | 15.5% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $133.97 | 15.3% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $105.30 | 12.1% | 6 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $62.99 | 7.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.77 | 7.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.84 | 5.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.84 | 5.4% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.83 | 4.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.19 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.23 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.08 | 1.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.85 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $873.03 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $153.51 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $133.97 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.66 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $105.30 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $77.48 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.57 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.60 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.77 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $48.84 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.84 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.84 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $37.83 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.82 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.73 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $5.94 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $3.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 118 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 60 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 169 |
| Levothyroxine Sodium | Levothyroxine Sodium | 555 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 454 | 127 |
| Losartan Potassium | Losartan Potassium | 314 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 310 | 88 |
| Omeprazole | Omeprazole | 300 | 84 |
| Alprazolam | Alprazolam | 284 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 263 | 74 |
| Metformin Hcl Er | Metformin Hcl | 244 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 213 | 61 |
| Lisinopril | Lisinopril | 206 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 60 |
| Trazodone Hcl | Trazodone Hcl | 203 | 57 |
| Gabapentin | Gabapentin | 202 | 51 |
| Simvastatin | Simvastatin | 199 | 53 |
| Meloxicam | Meloxicam | 187 | 59 |
| Glimepiride | Glimepiride | 182 | 51 |
| Ezetimibe | Ezetimibe | 175 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 170 | 50 |
| Metformin Hcl | Metformin Hcl | 165 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 159 | 45 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 147 | 121 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 39 |
| Furosemide | Furosemide | 136 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 133 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 37 |
| Methylprednisolone | Methylprednisolone | 125 | 103 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 38 |
| Eliquis | Apixaban | 118 | 25 |
| Celecoxib | Celecoxib | 111 | 27 |
| Carvedilol | Carvedilol | 110 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 43 |
| Montelukast Sodium | Montelukast Sodium | 110 | 33 |
| Tramadol Hcl | Tramadol Hcl | 109 | 26 |
| Allopurinol | Allopurinol | 105 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 84 | 68 |
| Donepezil Hcl | Donepezil Hcl | 80 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 19 |
| Potassium Chloride | Potassium Chloride | 78 | 29 |
| Alendronate Sodium | Alendronate Sodium | 76 | 23 |
| Ozempic | Semaglutide | 74 | 14 |
| Chlorthalidone | Chlorthalidone | 71 | 18 |
| Buspirone Hcl | Buspirone Hcl | 70 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 20 |
| Synthroid | Levothyroxine Sodium | 67 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 20 |
| Lovastatin | Lovastatin | 63 | 19 |
| Mounjaro | Tirzepatide | 62 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 23 |
| Clonazepam | Clonazepam | 61 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 15 |
| Jardiance | Empagliflozin | 60 | 15 |
| Xarelto | Rivaroxaban | 57 | 15 |
| Atenolol | Atenolol | 56 | 15 |
| Sertraline Hcl | Sertraline Hcl | 54 | 17 |
| Meclizine Hcl | Meclizine Hcl | 52 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 24 |
| Estradiol | Estradiol | 49 | 13 |
| Finasteride | Finasteride | 48 | 12 |
| Terazosin Hcl | Terazosin Hcl | 47 | 13 |
| Nifedipine Er | Nifedipine | 46 | 12 |
| Januvia | Sitagliptin Phosphate | 45 | 14 |
| Mupirocin | Mupirocin | 44 | 29 |
| Methocarbamol | Methocarbamol | 43 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 13 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 41 | 13 |
| Azithromycin | Azithromycin | 39 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 34 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 19 |
| Famotidine | Famotidine | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | 11 |
| Cefdinir | Cefdinir | 31 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 25 |
| Azelastine Hcl | Azelastine Hcl | 30 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 18 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 14 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | 11 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 18 |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $873.03 · 62 records | Novo Nordisk Inc | CAMZYOS, CREON, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, HORIZANT, HYQVIA, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error